États-Unis · Plateformes & données · Finviz

Relmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026

Publié par Finviz · États-Unis il y a 20 h

Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous…

Lire l'article complet sur Finviz Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (finviz.com)

Relmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026

À lire aussi

Big Tech’s $500 billion spending spree leaves a lot less for shareholders

ConocoPhillips Q3 preview: High expectations as upstream focus drives growth

IPG Photonics: 3 Key Takeaways for Long-Term Investors

Democrats win control of Congress as voters rebuke Trump agenda

Treasury yields fall after Democrats win House and Senate majorities

Best Stocks Under $5

Relmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026

Partager

À lire aussi

Big Tech’s $500 billion spending spree leaves a lot less for shareholders

ConocoPhillips Q3 preview: High expectations as upstream focus drives growth

IPG Photonics: 3 Key Takeaways for Long-Term Investors

Democrats win control of Congress as voters rebuke Trump agenda

Treasury yields fall after Democrats win House and Senate majorities

Best Stocks Under $5